In Brief: Sanofi
This article was originally published in The Gray Sheet
Sanofi: Launches Fidia's Hyalgan hyaluronic acid-based knee osteoarthritis treatment product in the U.S. Following FDA approval of Fidia's PMA for Hyalgan May 28, the company submitted a letter to the agency informing it that Sanofi would be the U.S. distributor and making minor editorial changes to the labeling. FDA treated the submission as a PMA supplement, which was approved July 8 ("The Gray Sheet" Aug. 25, p. 10). Sanofi has a separate co-promotion pact with Orthologic for sales to orthopedic surgeons. Priced at $500 per unit, Hyalgan will face competition from Biomatrix' Synvisc HA product, which was approved Aug. 13 and is slated for release this fall ("The Gray Sheet", Aug. 18, p. 6)...
You may also be interested in...
Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.
Paracetamol, acetylcysteine and loperamide among list of OTC drugs deemed "essential" by Spain in the fight against coronavirus.
Mylan, in partnership with Indian firm Lupin, will be looking to rival Biogen and Sandoz by introducing an etanercept biosimilar in European markets following a positive opinion by the EMA’s CHMP on Mylan's application.